Background. Immunoglobulin A (IgA) nephropathy is the most common form of glomerulonephritis in the world, and a substantial number of patients develop end-stage renal disease (ESRD). Although there are several prognostic indicators, it remains difficult to predict the renal outcome in individual patients. Methods. A prospective cohort study was conducted in 97 clinical units in Japan from 1995 to 2002. We analysed the data from 2269 patients using proportional hazards models in order to determine the predictors of ESRD in IgA nephropathy and to develop a scoring system to estimate ESRD risk. Results. During the follow-up (median, 77 months), 207 patients developed ESRD. Systolic hypertension, proteinuria, hypoproteinaemia, azotaemia and a high histological grade at initial renal biopsy were independently associated with the risk of ESRD. Mild haematuria predisposed patients to ESRD more than severe haematuria. A scoring system was developed to estimate the 7-year ESRD risk from eight clinical and pathological variables. Actually, this prognostic score accurately classified patients by risk: patients with estimates of 0.0-0.9, 1.0-4.9, 5.0-19.9, 20.0-49.9, and 50.0-100.0% had a 0.2, 2.4, 12.2, 40.2 and 80.8% of ESRD incidence over 7 years, respectively. The corresponding area under the receiver operating characteristic curve was 0.939 [95% confidence interval (CI), 0.921-0.958]. This score was verified in repetitions of the derivation-validation technique.
Introduction
Immunoglobulin A (IgA) nephropathy is the most common form of glomerulonephritis in the world today [1] . When Berger and Hinglais [2] described this disease as a new clinical entity in 1968, clinicians regarded it as a benign nephropathy. However, successive studies indicated that 6-43% of IgA nephropathy patients would develop endstage renal disease (ESRD) over a period of 10 years [3, 4] .
Many investigators have tried to determine the prognostic indicators of this disease, which include elevated serum creatinine (sCr), heavy proteinuria, severe histological changes, hypertension, hypoproteinaemia, older age and male sex [4] [5] [6] [7] .
However, difficulties remain in predicting the renal outcomes in individual patients and determining those who need aggressive therapeutic intervention. This may be partly a result of the relatively small sample sizes used in previous studies [8] . We, therefore, set up a large-scale, nationwide prospective study in order to develop an IgA nephropathy prognostic score.
Subjects and methods

Patients and follow-up
The Research Group on Progressive Renal Diseases and the Research Committee on the Epidemiology of Intractable Diseases, both organized by the former Ministry of Health and Welfare of Japan (currently the Ministry of Health, Labor and Welfare), conducted a nationwide survey on IgA nephropathy in January 1995 [9] . This survey identified 5324 patients with biopsy-proven IgA nephropathy, who had visited general physicians, nephrologists, paediatricians or urologists in Japan during 1994.
Follow-up was carried out at clinical units that had 10 or more IgA nephropathy patients in the survey. When more than 50 of them were identified in a unit, we randomly selected 50 to reduce the burden on the unit. We eventually designated 3409 patients as potential subjects for the followup study and undertook the first mail survey in May 1997. The response rate was 82.5% in a patient base. A second mail survey was conducted for 2350 cases in August 1999, and a third for 2285 cases in November 2002, with response rates of 95.7 and 93.3%, respectively. Excluding those who had died, who had developed ESRD before baseline, or whose essential baseline data were missing, we included 2269 eligible patients for the analyses from 97 clinical units. Figure 1 shows their distribution by sex and age. There are two peaks in age distribution: 15-24 and 40-49 years. The median follow-up period was 77 months (range, 1-94 months).
This investigation was approved by the Ethics Committee of the Kyoto University Graduate School of Medicine and the Ethics Committee of the Juntendo University School of Medicine.
Data collection
The baseline data of the patients were obtained by reviewing medical records in the nationwide survey in 1995. The data included sex, age, year of diagnostic renal biopsy, systolic and diastolic blood pressure, urine protein and blood, serum total protein and albumin and sCr. Proteinuria was semiquantified with a standard urine dipstick with (À), (þÀ), (þ), (þþ) and (þþþ) corresponding to <10, 10-29, 30-99, 100-299 and !300 mg/dl of urine albumin, respectively. Histological grade at initial renal biopsy was reassessed by pathologists or nephrologists in each participating hospital at the first follow-up survey using the new criteria from the Joint Committee of the Research Group on Progressive Renal Diseases and the Japanese Society of Nephrology (Table 1) [10] . This reassessment was needed because the classification criteria were established after our baseline survey. In the three follow-up surveys, information on outcomes such as death, ESRD and sCr was collected by mail.
Statistical analysis
Predictors of ESRD. The primary endpoint in this study was ESRD, which was defined as the initiation of dialysis therapy. The follow-up period for each patient was calculated in months from the data of the nationwide survey on ESRD, death or the last visit. Those who died without ESRD were treated as censored cases.
The 7-year cumulative incidence (risk) of ESRD was computed by the Kaplan-Meier method [11] according to demographic and clinical characteristics. The rate ratios (RRs) Cellular infiltration is slight in the interstitium except around some sclerosed glomeruli. Tubular atrophy is slight, and mild vascular sclerosis is observed. IV Severe, diffuse mesangial cell proliferation and increased matrix. Glomerulosclerosis, crescent formation or adhesion to the Bowman's capsule seen in >30% of all biopsied glomeruli. When sites of sclerosis are totalled and converted to global sclerosis, the sclerosis rate is >50% of all glomeruli. Some glomeruli also show compensatory hypertrophy. The sclerosis rate is the most important of these indices.
Interstitial cellular infiltration and tubular atrophy, as well as fibrosis are seen. Hyperplasia or degeneration may be seen in some intrarenal arteriolar walls. for ESRD were estimated by potential prognostic factors using proportional hazards models [12] . The independent effect of each variable was assessed by multivariate analysis. Diastolic blood pressure and serum albumin were excluded from the multivariate model because of their close relation with systolic blood pressure and serum total protein, respectively. To test for a linear trend, we coded each stratum of the variable as 0, 1, 2, . . . and included it as a continuous variable in the proportional hazards model [13] . For variables that displayed 'U-shape' or 'inverted U-shape' relationships with ESRD risk, we also analysed non-linear associations using a quadratic model [14] . Subjects with missing values were omitted from the relevant analysis.
Construction of scoring system. A scoring system to predict ESRD in individual patients with IgA nephropathy was based on the proportional hazards model. It included sex, age and all the significant variables in the aforementioned multivariate analysis. In this model, a patient with covariate values X 1 , X 2 , . . ., X n has an expected renal survival rate (¼ 1 À cumulative incidence of ESRD) at time t, S (t), formulated as:
þb n XnÞ
where S 0 (t) is the baseline survivor function and b 1 , b 2 , . . ., b n are the coefficients estimated from the model [8, 15] . The RRs are exponents of these b coefficients. We stratified the patients by each prognostic factor and applied a proportional hazards model with dummy variables (0 or 1 for X 1 , X 2 , . . ., X n ). The scores derived from the b coefficients were smoothed by linear interpolation in each stratum of the variables and were then multiplied by 10 to simplify the calculation. The sum of all the scores for individual factors (total score) was 10
, and a corresponding ESRD risk, 1 À S (t), was computed from the total score. The baseline survivor function, S 0 (t), was estimated by the product-limit method using the PHREG procedure of the Statistical Analysis System [16] .
Validation of scoring system. To examine the goodness of fit of the scoring system to the data, we divided the patients into five groups according to the predicted 7-year risk of ESRD, that is, minimum (0.0-0.9%), low (1.0-4.9%), moderate (5.0-19.9%), high (20.0-49.9%) and very high (50.0-100.0%). The renal survival curve of ESRD was then drawn in each group using the Kaplan-Meier method [11] . To further assess the utility of the score, we used the area under the receiver operating characteristic (ROC) curve [17] for the 7-year risk of ESRD. The area and its 95% confidence interval (CI) were estimated by the nonparametric method [17] .
As an additional analysis [18] , one-third (n ¼ 756) of the subjects were randomly allocated to a validation sample and the remainder to a derivation sample. The prognostic score was developed in the derivation sample, and the actual 7-year cumulative incidence of ESRD was computed by the predicted risk in the validation sample [11] . The area under the ROC curve was also estimated in the validation group. Considering the sampling error, we repeated this procedure in 100 different validation sets. Smoothing of the scores was not done in this analysis.
Results
During the follow-up of 11 923.5 person-years, 207 patients with IgA nephropathy developed ESRD. Sixteen deaths without ESRD were also reported: five from circulatory diseases, five from cancer and six from unknown causes. Table 2 summarizes the 7-year cumulative incidence and RR for ESRD by demographic and clinical factors. Patients with no or only mild proteinuria [urine protein of (À) or (þÀ)] had an appreciably lower risk of ESRD: their 7-year cumulative incidence was 0.7% (95% CI, 0.0-1.5%). In contrast, patients with excretional impairment at baseline had a much higher risk. Their 7-year cumulative incidences were 68.5% (95% CI, 59.2-77.8%) and 90.1% (82.4-97.8%) for sCr of 1.68-2.50 and !2.51 mg/dl (148-221 and !222 mmol/l), respectively. The proportion was as high as 25.9% (95% CI, 19.2-32.6%) even among those with mild azotaemia [sCr, 1.26-1.67 mg/dl (112-147 mmol/l)]. A univariate analysis with proportional hazards models revealed that earlier renal biopsy, systolic/diastolic hypertension, proteinuria, hypo-proteinaemia/albuminaemia, azotaemia and a higher histological grade at initial renal biopsy had a strong dose-dependent association with the risk of ESRD. Systolic hypertension, proteinuria, hypoproteinaemia, azotaemia and a higher histological grade remained significant predictors in the multivariate analysis (trend P < 0.05).
Although male patients had a higher RR in the univariate analysis, the high risk disappeared when considering other factors. Patients in their 30s were at the lowest risk in the multivariate analysis, whereas an upward trend in RR with advancing age was found in the univariate model. Mild haematuria [<30 red blood cells per high-power field (RBC/HPF)] was associated with a higher risk compared with severe haematuria (!30 RBC/HPF) in both the univariate and multivariate analyses. In the multivariate models, we found a significant non-linear association of haematuria with ESRD risk (P for non-linear association <0.0001) but none for age (P ¼ 0.26).
Based on these analyses, we established a scoring system to estimate 4-and 7-year cumulative incidence rates of ESRD. Of the 2269 patients included in this study, 1754 (77.3%) had a complete data set needed for our system designing. Table 3 lists the scores of individual prognostic factors. The total score (sum of individual scores) can then be converted to the corresponding estimated risk using Table 4 . The baseline survivor function, S 0 (t), was estimated as 0.99955026 and 0.99887700 at 4 and 7 years, respectively. An illustrative example of how to apply this scoring system to patients with IgA nephropathy follows. The patient is a 59-year-old man with systolic blood pressure of 142 mmHg, proteinuria of (þþ), haematuria of !30 RBC/HPF, serum total protein of 6.6 g/dl, histological grade of IV at initial renal biopsy, and sCr of 1.35 mg/dl. As shown in Table 3 , the scores Table 2 . for sex, age, systolic blood pressure, proteinuria, haematuria, serum total protein, histological grade and sCr are À2, À3, 3, 20, 3, 5, 9 and 11, respectively. Thus, the total score is calculated to be 46 Table 4 , this total score of 46 can be converted to a 4-and 7-year ESRD risk of 4.4 and 10.6%, respectively. The actual renal survival (¼ 1 À cumulative incidence of ESRD) according to the estimated 7-year risk was plotted in Figure 2 The influence of therapy could not be taken into account in the scoring system, because data on treatment were not collected at baseline and only the history of use (yes or no) of six groups of drugs (antiplatelet agents, corticosteroids, immunodepressants, angiotensin-converting enzyme inhibitors, calcium channel blockers and fish oil, and others) [19, 20] at the 1997 survey was available for most of the cases. The drugs had been used for 82.2, 35.3, 10.9, 29.2, 20.0 and 34.1% of the patients, respectively, until the 1997 survey. Additional multivariate analyses that included the history of drug use did not essentially alter the associations of clinical characteristics with the ESRD risk presented in Table 2 , except for the attenuation of risk for systolic blood pressure (data not shown).
Even when the prognostic scores were developed using derivation samples randomly selected from all subjects, the estimated 7-year cumulative incidence of ESRD well-predicted the observed ones in the remaining validation sample. 
Discussion
Based on a large-scale cohort study, we described the prognostic indicators for IgA nephropathy and developed a scoring system for estimating the ESRD risk. Systolic hypertension, proteinuria, haematuria, hypoproteinaemia, azotaemia and a high histological grade at initial renal biopsy were related to the risk, independent of other factors. The prognostic score successfully classified patients according to their ESRD risk and was verified by the analysis, dividing the subjects into derivation and validation samples.
To the best of our knowledge, this is the largest follow-up study to date on the renal outcome of IgA nephropathy. The present investigation enrolled many IgA nephropathy patients at various clinical stages, which enabled us to quantify ESRD risk by prognostic factors in detail. Whereas most studies to date followed IgA nephropathy patients from the time of initial renal biopsy or diagnosis [4] , our study included patients at different stages. Therefore, the prognostic score can be applied appropriately whenever needed. Use of clinical data subsequent to renal biopsy may improve the prediction of renal outcome [4] . As expected from previous studies [3] [4] [5] [6] [7] , hypertension, proteinuria, hypoproteinaemia, higher sCr and more severe morphological changes were independent risk factors for ESRD. Mild haematuria (<30 RBC/HPF) was related to a higher risk of ESRD than the more severe type (!30 RBC/HPF). This supports the clinical impression that gross haematuria is a good sign [8] , although the association still remains controversial [4] and its mechanism not yet fully understood. The reproducibility of severe haematuria was not so high as that of proteinuria.
The potential misclassification, if any, will attenuate the actual difference in ESRD risk between the groups of mild and severe haematuria. Considering repeated measures of haematuria may serve to further clarify the poor prognosis associated with mild haematuria.
The lower the glomerular filtration rate (GFR) of a patient reflected in higher sCr, the sooner the patient will reach ESRD if the rate of decline in GFR is the same.
Male patients were at an increased risk of ESRD in the univariate analysis, but that finding disappeared in the multivariate model. The sCr level is essentially higher in men than in women due to the greater production of creatinine in males [21] . Nevertheless, the decision when to start haemodialysis is made mainly based on the sCr level irrespective of sex. Thus, male sex would seemingly be a risk factor for ESRD. In fact, it was not a risk factor after adjustment for sCr, but the elevated risk among men appeared again in the proportional hazards model excluding 1/sCr (RR, 1.49; 95% CI, 1.05-2.10). A U-shaped association was found between age and ESRD risk after adjustment for other prognostic factors, though the non-linear association was not statistically significant. Age was positively associated with the ESRD risk in previous univariate analyses [4] , whereas negative associations were observed in preceding multivariate ones [7, 22] . Most of these studies treated age as a single continuous variable in the multivariate model. Our 10-year stratification of age revealed a possible non-linear relationship.
We proposed a new scoring system for the prediction of renal outcome in individual IgA nephropathy patients. Compared with several previous studies providing prognostic measures according to clinicopathological factors, our system has some advantages in terms of background data and target outcome. First, it is based on the data from a much larger sample than the one in a previous study by Beukhof et al. [8] . Second, it predicts the risk of ESRD, rather than that of surrogate endpoints such as an increase in sCr [15] . Although D'Amico and coworkers [23] developed a scoring index using proteinuria and three histological variables, and Frimat and colleagues [24] developed a classification using sCr and 24-h proteinuria, both of which correlated well with renal survival [23, 24] , the ESRD risk was not quantified in these two studies. Our scoring system can quantitatively estimate the ESRD risk in IgA nephropathy patients, using clinical and pathological information collected in routine medical practice.
As shown in Figure 2 and the ROC analysis, our prognostic score works well; even when it is based on randomly selected derivation samples, the score predicted the ESRD risk in the remaining validation sample as accurately as the score derived from the whole dataset. Thus, our estimates among all subjects were fully justified.
Some limitations should also be kept in mind when utilizing the score tables. First, our prognostic score is not able to predict ESRD risk for longer than 7 years (we are conducting a further survey to extend the follow-up period for a longer-term prediction). Second, the endpoint of the present study was focused on ESRD. Although this follow-up study collected sCr values as an outcome in addition to ESRD and deaths, the analytical methods for the change in sCr level over time greatly differ from those for ESRD. We, therefore, will report analyses for the change in sCr values as an outcome after the ongoing extended survey is completed. Third, we did not address the effect of therapy because data on treatment were not obtained at baseline. Further investigations focusing on treatment may be warranted. 
